1 Russel CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for SARS-CoV-2 lung injury. The Lancet, 2020. DOI:10.1016/S0140-6736(20)30317-2.
2 World Health Organization: Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim Guidance [EB/OL](2020-01-28)[2020-02-05]
3 Tan YJ , Lim SG , Hong W. Understanding the accessory viral proteins unique to the severe acute respiratory syndrome ( SARS ) coronavirus [ J ] .Antiviral Res , 2006 , 72 ( 2 ): 78-88
4 Jo S , Kim H , Kim S , Shin DH , Kim MS . Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Chem Biol Drug Des 2019 Dec;94 (6): 2023-2030
5 Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, Zhu J, Zhang Q, Wu J, Liu L. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020 Feb 26. doi: 10.1002/jmv.25726.
6 Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2infection. J Med Virol. 2020 Feb 26. doi: 10.1002/jmv.25725.
7 Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, Wang Y, Guo X. Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2and SARS-CoV.Viruses. 2020 Feb 22;12(2). pii: E244. doi: 10.3390/v12020244.
8 Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020 Feb 24. doi: 10.1038/s41564-020-0688-y.
9 Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, Li J, Wang H, Yu L, Huang H, Qiu Y, Wei G, Fang Q, Zhou J, Sheng J, Liang T, Li L. [Management of coronavirus disease-19 (COVID-19): the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Feb 21;49(1):0. Chinese.
10 Tong ZD, Tang A, Li KF, Li P, Wang HL, Yi JP, Zhang YL, Yan JB. Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis. 2020 May 17;26(5). doi: 10.3201/eid2605.200198. [Epub ahead of print]
11 Qin C, Liu F, Yen TC, Lan X. F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases. Eur J Nucl Med Mol Imaging. 2020 Feb 22. doi: 10.1007/s00259-020-04734-w. [Epub ahead of print]
12 Su B, Wang Y, Zhou R, Jiang T, Zhang H, Li Z, Liu A, Shao Y, Hua W, Zhang T, Wu H, He S, Dai L, Sun L. Efficacy and Tolerability of Lopinavir/Ritonavir- and Efavirenz-Based Initial Antiretroviral Therapy in HIV-1-Infected Patients in a Tertiary Care Hospital in Beijing, China. Front Pharmacol. 2019 Dec 12;10:1472.
13 Wu CY, Jan JT, Ma SH , et al. Small molecules targeting severe acute respuatory Syndrome human coronavirus [ J]. Proc Naù Acad Sci U S A , 2004,101 (27) : 10012-10017
14 Hung KKC, Mark CKM, Yeung MPS, Chan EYY, Graham CA. The role of the hotel industry in the response to emerging epidemics: a case study of SARS in 2003 and H1N1 swine flu in 2009 in Hong Kong.Global Health. 2018 , 14(1):117.
15 Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015,212(12):1904-13.
16 de Wilde AH, Falzarano D, Zevenhoven-Dobbe JC, Beugeling C, Fett C, Martellaro C, Posthuma CC, Feldmann H, Perlman S, Snijder EJ.Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.Virus Res. 2017, 228:7-13
17 Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bushmaker T, Martellaro C, Baseler L, Benecke AG, Katze MG, Munster VJ, Feldmann H. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques.Nat Med. 2013, 19(10):1313-7.
18 Channappanavar R , Fehr AR , Zheng J , Wohlford-Lenane C , Abrahante JE , Mack M , Sompallae R , McCray PB , Meyerholz DK , Perlman S . IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest 2019, 130 3625-3639.
19 Falzarano D , de Wit E , Rasmussen AL , Feldmann F , Okumura A , Scott DP , Brining D , Bushmaker T , Martellaro C , Baseler L , Benecke AG , Katze MG ,Munster VJ , Feldmann H . Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013 Oct;19 (10): 1313-7
20 Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA. Therapeutic options for Middle East respiratory s yndrome coronavirus
(MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis. 2013. 17(10): e792 -8.
21Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH ; Hassan, Deif H, LaMere EA, Chang M, Kain KC, Farcas GA, Ferguson P, Latchford M, Levy G, Dennis JW, Lai EY, Fish EN. Interferon alfacon-1 plus corticosteroids in severe acute respiratory s yndrome: a preliminary study. JAMA. 2003. 290(24): 3222-8.
22 Kaur S, Prasad N, Srivastava A, Kumari M, Singh S, Kumar D, Bhattacharyya R, Banerjee D. Fluorescence spectra of chloroquine suspension: A probable tool for quality assessment of the most common antimalarial in a user-friendly manner.Indian J Pharmacol. 2019,51(6):416-417.
23 de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014, 58(8):4875-84.
24 Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020 Feb 15:105923. doi: 10.1016/j.ijantimicag.2020.105923.